阿加曲班联合依达拉奉治疗心房颤动合并脑栓塞的临床效果

Abstract
Figure/Table
References (15)
Related Citation (8)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical efficacy of Argatroban combined with Edaravone in the treatment of atrial fibrillation complicated with cerebral embolism.Methods76 patients with atrial fibrillation and cerebral embolism admitted into our hospital from March 2014 to May 2016 were selected.Based on dynamic random classification,they were divided into research group (n=38)and control group (n=38).The patients in the control group were treated with Low Molecular Weight Heparin and the patients in the research group were treated with Argatroban combined with Edaravone.The score of national institutes of health stroke scale （NIHSS),Barthel score of activities of daily living,and coagulation indicator between two groups were compared.ResultsThere was no statistical difference in NIHSS score or Barthel score between two groups before treatment(P＞0.05).After therapy,the score of NIHSS was(9.15±2.12)points, and Barthel score was（76.57±14.23)points,which caught great superiority in comparison with those in the control group [(15.47±4.35)points,(58.45±12.31)points](P＜0.05).No great difference was displayed in the coagulation indicator before treatment(P＞0.05),but after therapy,the advantage was greater in the research group compared with that in the control group (P＜0.05).ConclusionArgatroban combined with Edaravone in the treatment of atrial fibrillation complicated with cerebral embolism can effectively improve neurologic impairment,ability of daily life activities,as well as coagulation indicator,which is worthy of widespread promotion in clinic.

Key words： Argatroban Edaravone Atrial fibrillation Cerebral embolism Coagulation indicator

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Chun
	ZHU Fei
	HU Xi-hui

Cite this article:

HUANG Chun,ZHU Fei,HU Xi-hui. Clinical effect of Argatroban combined with Edaravone in the treatment of atrial fibrillation complicated with cerebral embolism[J]. 中国当代医药, 2016, 23(36): 39-41.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I36/39

[1]	唐铠，伍建国，李秋，等.心脏瓣膜置换术后动态监测血栓前体蛋白的临床价值分析[J].中国当代医药，2014，21（17）：21-23.
[2]	易晓淑，章丽萍，孙慧超，等.应用低分子肝素钠预防房颤患者住院期间心源性脑栓塞的临床研究[J].中国医药导报，2013，10（20）：149-150，153.
[3]	戴晓岚.阿加曲班联合依达拉奉治疗房颤合并脑栓塞的临床疗效评价[J].中国药房，2011，22（22）：2075-2077.
[4]	Kim SJ，Shin HY，Ha YS，et al.Paradoxical embolism as a cause of silent brain infarctions in healthy subjects：the ICONS study（Identification of the Cause of Silent Cerebral Infarction in Healthy Subjects）[J].Eur J Neurol，2013，20（2）：353-360.
[5]	刘伟，崔晓朋.瑞替辅酶联合依达拉奉治疗早期脑栓塞8例临床疗效分析[J].中国当代医药，2012，19（14）：56-57.
[6]	郭丽，郑翔丽，纪红，等.依达拉奉对心源性脑栓塞患者T淋巴细胞亚群及氧化应激水平的影响[J].海南医学院学报，2016，22（13）：1369-1372.
[7]	闫宏亮.瑞替辅酶与依达拉奉在早期脑栓塞治疗中的疗效观察[J].临床医药文献杂志（电子版），2016，3（24）：4904.
[8]	张桂茹.依达拉奉治疗急性脑栓塞的临床效果与不良反应分析[J].中国医药导刊，2016，18（9）：911-912.
[9]	杨宏煜.依达拉奉治疗脑血栓形成与脑栓塞的疗效差异分析[J].临床医药文献杂志（电子版），2014，1（9）：1535，1539.
[10]	孙贵祥，孙培丽，张爱萍.阿加曲班联合氯吡格雷治疗大动脉粥样硬化性脑梗死的临床研究[J].中国当代医药，2016，23（19）：72-74.
[11]	郭合伏，陈菊，庄素霞.依达拉奉联合阿加曲班治疗急性脑梗死的效果观察[J].中国当代医药，2015，22（28）：125-127.
[12]	于海玲.高压氧和依达拉奉治疗脑栓塞的疗效对比分析[J].航空航天医学杂志，2016，27（7）：842-844.
[13]	王雪.阿加曲班和低分子肝素钙治疗急性脑梗死的效果比较[J].中国医药，2016，11（4）：528-532.
[14]	魁学梅，杨彦彪，何忠芳，等.1例疑似依达拉奉注射液引起的急性肾衰竭[J].中国医院药学杂志，2015，35（16）：1525-1526.
[15]	刘琳，熊义豪.巴曲酶治疗房颤所致脑栓塞临床效果分析[J].现代诊断与治疗，2014，25（19）：4536-4537.